BioMarin to buy rare disease drugmaker Amicus for $4.8B

Acquisition Details - BioMarin Pharmaceutical has agreed to acquire Amicus Therapeutics for $4.8 billion, gaining two marketed drugs for rare diseases and a third asset in late-stage testing [1][2] - The acquisition is an all-cash deal, with BioMarin paying $14.50 per Amicus share, representing a 33% premium over Amicus' closing stock price prior to the announcement [2] Financial Impact - BioMarin anticipates that Amicus' medicines will enhance its long-term revenue growth through 2030 and beyond, with Galafold generating $371 million in revenue for Amicus in the first nine months of the year [3] - Amicus' second marketed product, a combination of Pombiliti and Opfolda, recorded $77 million in revenue during the same period [4] - If the acquisition closes, BioMarin's marketed therapies will increase to 10, contributing to a reported net product revenue of $2.3 billion from January to September, an 11% year-over-year increase [5] Strategic Fit - BioMarin's CEO described Amicus as an "exceptional strategic fit," expecting the deal to be accretive to non-GAAP diluted earnings per share within a year of closing [7] - Amicus has a potentially first-of-its-kind treatment for FSGS, an uncommon kidney disease, which could further expand BioMarin's portfolio [6]